Roche Offers More ARV Technology Transfer Deals

Swiss drugmaker Roche has expanded its Technology Transfer Initiative for the production of generic versions of the company's patented second line antiretroviral (ARV) Invirase (saquinavir) to four local manufacturers in Africa and Asia. The deal will allow saquinavir to be produced by Regal Pharmaceuticals in Kenya, CAPS Holdings in Zimbabwe, Shely's Pharmaceuticals in Tanzania and Bexmico Pharmaceuticals in Bangladesh. Already included in the initiative are South Africa's Aspen and Cosmos, and Universal Corporation in

To read the full article, please sign in or take a free trial.